About Protagen
Protagen is a Healthcare company based in Dortmund (Germany) founded in 1997, and was acquired by Oncimmune in March 2019. Autoantibody biomarkers are utilized for autoimmune disease diagnostics. Protagen has raised $19.84 million across 6 funding rounds from investors including Qiagen, NRW.Bank and Oncimmune. The company has 20 employees. The company was acqui-hired. Its focus areas include Life Sciences, Immunology, In Vitro Diagnostic Tests and Diversified. Its legal entity is Protagen AG.
Company details
Protagen is a provider of services, products and software solutions for protein research. Protagen provides products and GMP compliant services. The patented platform of protein expression libraries UNIclone allows Protagen the development of a new class of diagnostics based on autoantibody signatures in blood. Utilizing a personalized medicine approach, their multi-marker assay technology SeroTag; enables differential diagnosis and patient stratification for Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis and others. Protagen launched a research test in July 2014 for Systemic Sclerosis, secured by strong IP coverage and validated by proof-of concept studies in thousands of clinical samples.
- Headquarters Dortmund, Germany
- Employees 20
- Stage Acquired
- SectorsHealthcare
- Website protagen.com
- Social LinkedIn
- Acquired by Oncimmune (Mar 2019)
- Legal Name Protagen Ag
Funding Insights of Protagen
Protagen has successfully raised a total of $19.84M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $19.84M
- Total Rounds 6
- First Round $1.29M
(Apr 2005)
- Investors Count 6
All 6 funding rounds of Protagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | Series D | – | – | ||
| Sep 2010 | $12.88M | Series D | – | – | |
| Aug 2008 | Series C | – | – | ||
| Jan 2008 | $1.47M | Series C | – | – | |
| May 2006 | $4.2M | Series B | – | – | |
| Apr 2005 | $1.29M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Protagen
Protagen has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Qiagen, NRW.Bank and Oncimmune.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology companies are managed by MIG Fonds. | mig-fonds.de | Germany | ||
VC Firm funding companies in Europe | mig.ag | Munich, Germany | ||
Products and reagents for molecular diagnostic assays are supplied. | 1984 | qiagen.com | Hilden, Germany | |
Loans, advice, seminars, and networks are provided for financial support. | 2001 | nrwbank.de | Dusseldorf, Germany | |
A commercial bank providing deposits, loans, and payment services to customers. | svc-do.de | Dortmund, Germany | ||
Consumer and SME loans are provided across Germany. | 1948 | kfw.de | Frankfurt Am Main, Germany | |
Diagnostics and risk assessment solutions for lung cancer are developed. | 2006 | oncimmune.com | Nottingham, United Kingdom |
Investor details for Protagen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Protagen
4 dated milestones of Protagen across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Protagen is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series D,.
- Exit Acquired by Oncimmune.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Protagen
Complete news archive for Protagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Protagen
Protagen was founded in 1997 and raised its 1st funding round 8 years after it was founded.
Protagen is headquartered in Dortmund, Germany. It is registered at Dortmund, North Rhine-westphalia, Germany.
Protagen is a funded company, having raised a total of $19.84M across 6 funding rounds to date. The company's 1st funding round was a Series A of $1.29M, raised on Apr 2005.
Protagen has 20 employees.
Protagen is a provider of services, products and software solutions for protein research. Protagen provides products and GMP compliant services. The patented platform of protein expression libraries UNIclone allows Protagen the development of a new class of diagnostics based on autoantibody signatures in blood. Utilizing a personalized medicine approach, their multi-marker assay technology SeroTag; enables differential diagnosis and patient stratification for Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis and others. Protagen launched a research test in July 2014 for Systemic Sclerosis, secured by strong IP coverage and validated by proof-of concept studies in thousands of clinical samples.
Protagen operates through Protagen Ag.
Yes. Protagen was acquired by Oncimmune in March 2019.